Alland Leila has officially filed a Form 3, confirming her position as Chief Medical Officer at Cardiff Oncology, Inc. This filing, dated October 27, 2026, is significant as it underscores her ongoing role in the company’s leadership.

Cardiff Oncology, Inc., identified by CIK 0001213037, operates in the biological products sector, focusing on innovative therapies. The company is incorporated in Delaware and has its fiscal year ending on December 31. The recent filing reflects the company’s commitment to maintaining strong leadership as it navigates the complexities of the life sciences industry.

The filing indicates that Alland Leila is an officer of the company but does not hold a ten percent ownership stake. The document states, "Alland Leila is the Chief Medical Officer," emphasizing her key role in guiding the company’s medical and scientific strategy.

This update may affect various stakeholders, including employees, investors, and partners, as they look to the leadership for direction in the competitive landscape of biological products. The filing also highlights the importance of executive roles in shaping company strategies and innovations.

The filing does not say what happens next, leaving stakeholders to await further updates from Cardiff Oncology, Inc.

The filing also specifies that Alland Leila does not hold any securities, indicating a focus on her role rather than ownership stakes within Cardiff Oncology, Inc. This detail may suggest a strategic alignment with the company's objectives without the potential conflicts that can arise from stock ownership.

Additionally, the Form 3 filing confirms that Alland Leila's address is listed as c/o Cardiff Oncology, Inc., located at 11055 Flintkote Avenue, San Diego, CA. This aligns her professional identity closely with the company’s operations in the life sciences sector.

It is noteworthy that Cardiff Oncology, Inc. was formerly known as Trovagene, Inc., with its name change occurring on March 4, 2013. This historical context may provide insights into the company's evolution and strategic shifts over the years.

The filing does not elaborate on specific initiatives or projects that Alland Leila may be currently involved in or any future plans for the company under her leadership. Stakeholders may be keen to learn more about her vision and strategic direction for Cardiff Oncology, Inc.